Theralase Technologies Inc.

OTCPK:TLTF.F Stock Report

Market Cap: US$54.6m

Theralase Technologies Management

Management criteria checks 4/4

Theralase Technologies' CEO is Roger Dumoulin-White, appointed in May 2023, has a tenure of 3.17 years. total yearly compensation is CA$410.00K, comprised of 97.6% salary and 2.4% bonuses, including company stock and options. directly owns 4.31% of the company’s shares, worth $2.35M. The average tenure of the management team and the board of directors is 15.9 years and 11.6 years respectively.

Key information

Roger Dumoulin-White

Chief executive officer

CA$410.0k

Total compensation

CEO salary percentage97.56%
CEO tenure3.2yrs
CEO ownership4.3%
Management average tenure15.9yrs
Board average tenure11.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roger Dumoulin-White's remuneration changed compared to Theralase Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-CA$4m

Dec 31 2025CA$410kCA$400k

-CA$4m

Sep 30 2025n/an/a

-CA$4m

Jun 30 2025n/an/a

-CA$4m

Mar 31 2025n/an/a

-CA$4m

Dec 31 2024CA$612kCA$400k

-CA$4m

Sep 30 2024n/an/a

-CA$4m

Jun 30 2024n/an/a

-CA$4m

Mar 31 2024n/an/a

-CA$4m

Dec 31 2023CA$405kCA$400k

-CA$5m

Compensation vs Market: Roger's total compensation ($USD291.13K) is below average for companies of similar size in the US market ($USD655.15K).

Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.

CEO

Roger Dumoulin-White

3.2yrs
Tenure
CA$410,000
Compensation

Mr. Roger John Dumoulin-White, B.Sc., P.Eng., Pro. Dir., is President and Chief Executive Officer of Theralase Technologies Inc. from May 2023 and also serves as it's Chairman and serves as it's Director s...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Dumoulin-White
President3.2yrsCA$410.00k4.31%
$ 2.4m
Kristina Hachey
CFO & Director22.2yrsCA$260.00k1.11%
$ 604.8k
Arkady Mandel
Chief Scientific Officer & Director15.4yrsCA$310.00k0.17%
$ 91.1k
David Groves
President of World Trade Division19.7yrsno datano data
Terry Ruch
Equine Medical Consultant15.9yrsno datano data
15.9yrs
Average Tenure

Experienced Management: TLTF.F's management team is seasoned and experienced (15.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Dumoulin-White
President23.5yrsCA$410.00k4.31%
$ 2.4m
Kristina Hachey
CFO & Director7.1yrsCA$260.00k1.11%
$ 604.8k
Arkady Mandel
Chief Scientific Officer & Director8.1yrsCA$310.00k0.17%
$ 91.1k
Randy Bruder
Independent Director18.5yrsCA$10.00k0.64%
$ 348.6k
Matthew Perraton
Independent Director13.4yrsCA$10.00k0.055%
$ 30.1k
Guy Anderson
Independent Director13.4yrsCA$10.00k0.14%
$ 75.4k
Ashish Kamat
Member of Medical & Scientific Advisory Board11.6yrsno datano data
Michael O'Donnell
Member of Medical & Scientific Advisory Board3.5yrsno datano data
Kaouthar Lbiati
Independent Director3.1yrsCA$10.00k0.083%
$ 45.5k
11.6yrs
Average Tenure

Experienced Board: TLTF.F's board of directors are seasoned and experienced ( 11.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 22:44
End of Day Share Price 2026/07/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Theralase Technologies Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre UddinResearch Capital Corporation